Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.45 |
| ▸ | NPY1R | P25929 | 6/20 | 0.45 |
| ▸ | NPY2R | P49146 | 4/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | OTC | P00480 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27086388 | 1.00 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RTGFBR1 | |
| SCHEMBL27086399 | 1.00 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RTGFBR1 | |
| SCHEMBL30415405 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RTGFBR1 | |
| SCHEMBL30632099 | 0.92 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RTGFBR1 | |
| SCHEMBL29486955 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RTGFBR1 | |
| SCHEMBL29789058 | 0.92 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30812975 | 0.92 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29636372 | 0.92 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL31091376 | 0.91 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL288599 | 0.91 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | claimed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | claimed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | claimed |
| WO-2022069704-A2 | IMMUNODIAGNOSTIC AGENTS AND METHODS FOR THE DETECTION AND DIFFERENTIATION OF CORONAVIRUS INFECTIONS | INSTITUT FÜR MOLEKULARE DIAGNOSTIK UND BIOANALYTIK (IMDB) GGMBH (DE) | 2022-04-07 | — | — | WO | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-108350035-B | Cyclic polypeptides, methods for obtaining them and their use in therapy | 埃克斯欧力提斯药物公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122070294-A | Stable vitreous material based on histidine, arginine and glutamic acid amino acids | 阵序补丁有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260079166-A1 | METHODS FOR DETECTING FRACTURE-RELATED INFECTION (FRI) | UNIV INDIANA TRUSTEES (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2026042013-A1 | MITOCHONDRIAL THERAPY | INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL (IOB) (CH) | 2026-02-26 | — | — | WO | disclosed |
| US-12552854-B2 | Peptides that block presentation of antigenic islet peptides by HLA-DQ8 and methods for treating type-1 diabetes | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4010353-A1 | PEPTIDES THAT BLOCK PRESENTATION OF ANTIGENIC ISLET PEPTIDES BY HLA-DQ8 AND METHODS FOR TREATING TYPE-1 DIABETES | Icahn School of Medicine at Mount Sinai (US) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022069704-A2 | IMMUNODIAGNOSTIC AGENTS AND METHODS FOR THE DETECTION AND DIFFERENTIATION OF CORONAVIRUS INFECTIONS | INSTITUT FÜR MOLEKULARE DIAGNOSTIK UND BIOANALYTIK (IMDB) GGMBH (DE) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | disclosed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | disclosed |
| EP-1549667-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031218-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | NPY4R 1571/4885NPY1R 565/4885NPY2R 504/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | NPY4R 238/4885NPY1R 247/4885NPY2R 187/4885 |
| US-12552854-B2 | Peptides that block presentation of antigenic islet peptides by HLA-DQ8 and methods for treating type-1 diabetes | IAPP, HLA-DRB1, MICA | NPY4R 49/4885NPY1R 15/4885NPY2R 45/4885 |
| US-20260079166-A1 | METHODS FOR DETECTING FRACTURE-RELATED INFECTION (FRI) | FGF23, FGB, SFRP1 | NPY4R 1200/4885NPY1R 1387/4885NPY2R 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.